Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of 5 µg]) delivered by the Respimat® Inhaler on exercise endurance time during constant work rate cycle ergometry in patients with Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim Pharma GmbH & Co. KG0 个研究点目标入组 150 人2009年11月18日

适应症Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary disease

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Chronic Obstructive Pulmonary Disease (COPD)
发起方: Boehringer Ingelheim Pharma GmbH & Co. KG
入组人数: 150
状态: 进行中（未招募）
最后更新: 14年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2009年11月18日

结束日期

待定

最后更新

14年前

研究类型

Interventional clinical trial of medicinal product

性别

All

研究者

发起方

Boehringer Ingelheim Pharma GmbH & Co. KG

入排标准

入选标准

•1\. All patients must sign an informed consent consistent with ICH\-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions
•2\. All patients must have a diagnosis of chronic obstructive pulmonary disease (P06\-12085\) and must meet the following spirometric criteria:
•Patients must have relatively stable airway obstruction with a post\-bronchodilator FEV1 \<80% of predicted normal (ECSC, Quanjer et al, Eur Respir J, 1993\) and a post\-bronchodilator FEV1/FVC \<70% at Visit 1 (ECSC predicted normal equations)
•3\. Male or female patients, between 40 and 75 years of age
•4\. Patients must be current or ex\-smokers with a smoking history of more than 10 pack years:
•Pack Years \= Number of cigarettes/day
•20 cigarettes/pack x years of smoking
•Patients who have never smoked cigarettes must be excluded
•5\. Patients must be able to perform technically acceptable pulmonary function tests (body plethysmography, spirometry), must be able to complete multiple symptom\-limited cycle ergometry tests, and must be able to maintain records (Patient Daily Diary) during the study period as required in the protocol
•6\. Patients must be able to inhale medication in a competent manner from the Respimat® inhaler and from a metered dose inhaler (MDI)

排除标准

•1\. Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient’s ability to participate in the study
•2\. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT \>x2 ULN, SGPT \>x2 ULN, bilirubin \>x2 ULN or creatinine \>x2 ULN will be excluded regardless of clinical condition (a repeat laboratory evaluation will not be conducted in these patients)
•3\. Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count 600/mm3, source documentation is required to verify that the increased eosinophil count is related to a non\-asthmatic condition.
•4\. Patients with any of the following conditions:
•\- a diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2\-agonists)
•\- a diagnosis of paroxysmal tachycardia (\>100 beats per minute) (due to the known class side effect profile of ß2\- agonists)
•5\. Patients with any of the following conditions:
•\-a history of myocardial infarction within 1 year of screening visit (Visit 1\)
•\-unstable or life\-threatening cardiac arrhythmia.
•\-hospitalized for heart failure within the past year.